China
Africa
Explore chapters and articles related to this topic
Piroxicam
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Patients who have a fixed drug eruption to oral piroxicam and a positive patch test on post-lesional skin may (or may not) show cross-reactions to tenoxicam (3,7,8,12), meloxicam (3,6), or droxicam (7). A man sensitized to thiosalicylic acid who developed photosensitivity from oral piroxicam, had positive photopatch tests to piroxicam and co-reactions to tenoxicam, droxicam and meloxicam (26).
Synthesis and in‐vivo taste assessment of meloxicam pivalate
Published in Drug Development and Industrial Pharmacy, 2019
Bandoo C. Chatale, Mariam S. Degani
Meloxicam (MX) is a nonsteroidal anti-inflammatory drug, widely used for management of arthritis and pain [3]. Patient noncompliance of MX is associated with the bitterness of the molecule. Various physical techniques have been developed to improve taste of formulations containing MX. MX oral dissolving films using polyvinylpyrrolidone and 2-hydroxypropyl-β-cyclodextrin (2-HP-β-CD) polymer fiber materials or nanofiber mats have been developed using electrospinning process to obtain a stable, fast releasing, and taste-masking formulation [4]. Taste-masked MX orally disintegrating tablets with enhanced dissolution were prepared using combinations of ion exchange resins and 2-HP-β-CD to mask the bitter taste and enhance dissolution of MX [5,6]. Another effective method for taste improvement is the chemical modification approach that is prodrug synthesis. Prodrugs of nonsteroidal anti-inflammatory drugs have been synthesized to reduce bitter taste as well as side effects such as ulceration potential due to irritation of gastrointestinal mucosa [7]. These prodrugs include guiacol ester of ibuprofen, nitroxybutylesters of flurbiprofen, ketoprofen, and prodrugs of piroxicam such as ampiroxicam, droxicam, and pivoxicam [8–12]. However, the prodrug development of MX has not been reported previously.